0000000000653157

AUTHOR

A. Markivskyy

showing 1 related works from this author

Pimasertib (PIM) versus dacarbazine (DTIC) in patients (pts) with cutaneous NRAS melanoma: a controlled, open-label phase II trial with crossover

2016

0301 basic medicineOncologyNeuroblastoma RAS viral oncogene homologmedicine.medical_specialtybusiness.industryMelanomaHematologymedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicinePimasertibIn patientDacarbazine - DTICOpen labelbusinessAnnals of Oncology
researchProduct